SLS SELLAS LIFE SCIENCES GROUP I revenue, earnings and financials
For the quarter ended June 30, 2026, SELLAS LIFE SCIENCES GROUP I reported revenue of n/a, net income of −$9.61M and diluted EPS of −$0.05; for the fiscal year ended December 2025 revenue was n/a.
SLS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$28.3M, net income −$26.9M (margin n/a), EPS −$0.25
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$31.5M, net income −$30.9M (margin n/a), EPS −$0.50
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$37.9M, net income −$37.3M (margin n/a), EPS −$1.34
- Fiscal year ended Dec 2022: revenue $1.00M, gross profit n/a, operating income −$42.0M, net income −$41.3M (margin -4130.1%), EPS −$2.13
- Fiscal year ended Dec 2021: revenue $7.60M, gross profit n/a, operating income −$25.3M, net income −$20.7M (margin -272.4%), EPS −$1.34
SLS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$9.61M, EPS −$0.05
- Quarter ended Mar 31, 2026: revenue n/a, net income −$8.41M, EPS −$0.05
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$7.66M, EPS −$0.05
- Quarter ended Sep 30, 2025: revenue n/a, net income −$6.79M, EPS −$0.06
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.60M, EPS −$0.07
- Quarter ended Mar 31, 2025: revenue n/a, net income −$5.81M, EPS −$0.07
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$6.74M, EPS −$0.06
- Quarter ended Sep 30, 2024: revenue n/a, net income −$7.11M, EPS −$0.10
- Quarter ended Jun 30, 2024: revenue n/a, net income −$7.47M, EPS −$0.13
- Quarter ended Mar 31, 2024: revenue n/a, net income −$9.57M, EPS −$0.21
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$8.14M, EPS −$0.23
- Quarter ended Sep 30, 2023: revenue $0, net income −$9.27M, EPS −$0.33
- Quarter ended Jun 30, 2023: revenue $0, net income −$8.84M, EPS −$0.31
- Quarter ended Mar 31, 2023: revenue $0 (down 100.0% year over year), net income −$11.1M, EPS −$0.47
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$9.12M, EPS −$0.33
- Quarter ended Sep 30, 2022: revenue $0, net income −$7.02M, EPS −$0.34
- Quarter ended Jun 30, 2022: revenue $0 (down 100.0% year over year), net income −$8.41M, EPS −$0.41
- Quarter ended Mar 31, 2022: revenue $1.00M (down 82.5% year over year), net income −$16.7M, EPS −$1.05
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$6.60M, EPS −$0.43
- Quarter ended Sep 30, 2021: revenue $0, net income −$7.09M, EPS −$0.45
SLS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$28.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$35.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$31.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$23.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$26.0M, share buybacks n/a
SLS balance sheet
- Jun 30, 2026: cash $138M, total assets $145M, total liabilities $7.73M, shareholders' equity $138M
- Mar 31, 2026: cash $107M, total assets $114M, total liabilities $6.77M, shareholders' equity $107M
- Dec 31, 2025: cash $71.8M, total assets $78.3M, total liabilities $7.47M, shareholders' equity $70.9M
- Sep 30, 2025: cash $44.3M, total assets $51.6M, total liabilities $5.93M, shareholders' equity $45.6M
- Jun 30, 2025: cash $25.3M, total assets $32.3M, total liabilities $6.16M, shareholders' equity $26.1M
- Mar 31, 2025: cash $28.4M, total assets $35.0M, total liabilities $7.20M, shareholders' equity $27.8M
- Dec 31, 2024: cash $13.9M, total assets $19.4M, total liabilities $9.97M, shareholders' equity $9.47M
- Sep 30, 2024: cash $21.0M, total assets $26.5M, total liabilities $10.6M, shareholders' equity $15.9M
Is SLS profitable?
No. SELLAS LIFE SCIENCES GROUP I lost $32.5M over the last four quarters.
What is SLS's EPS?
Diluted earnings per share over the last four quarters were −$0.21; −$0.05 in the latest quarter.